Rn Chemiceutics Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 17-12-2024
- Paid Up Capital ₹ 0.10 M
as on 17-12-2024
- Company Age 8 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.00 M
as on 17-12-2024
- Revenue -14.73%
(FY 2023)
- Profit 73.19%
(FY 2023)
- Ebitda -0.45%
(FY 2023)
- Net Worth 11.70%
(FY 2023)
- Total Assets 15.21%
(FY 2023)
About Rn Chemiceutics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹4.00 M.
Rajdeep Manedeshmukh and Rohit Manedeshmukh serve as directors at the Company.
- CIN/LLPIN
U85190PN2016PTC166604
- Company No.
166604
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Sep 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Rn Chemiceutics Private Limited offer?
Rn Chemiceutics Private Limited offers a wide range of products and services, including Test Strips, Urine Test Strip, IVDs & Analyzers, Immunoassay Analyzer, Hematology Analyzers, Abbott Blood Analyzer, Pulse Oximeter, Glucometer & POCT Devices, Cholesterol Checker, Urine Analyzer, Medical Laboratory Instruments.
Who are the key members and board of directors at Rn Chemiceutics?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajdeep Manedeshmukh  | Director | 28-Sep-2016 | Current |
| Rohit Manedeshmukh | Director | 28-Sep-2016 | Current |
Financial Performance of Rn Chemiceutics.
Rn Chemiceutics Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 14.73% decrease. The company also saw a substantial improvement in profitability, with a 73.19% increase in profit. The company's net worth Soared by an impressive increase of 11.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rn Chemiceutics?
Unlock access to Rn Chemiceutics's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Hemai Agro Producer Company LimitedActive 7 years 9 monthsRajdeep Manedeshmukh and Rohit Manedeshmukh are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 13 Apr 2022 | ₹4.00 M | Open |
How Many Employees Work at Rn Chemiceutics?
Unlock and access historical data on people associated with Rn Chemiceutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rn Chemiceutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rn Chemiceutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
